Sector News

Astellas sets up immune tolerance JV in $760m deal

June 4, 2015
Life sciences
Japanese drugmaker Astellas and Swiss biotech Anokion have hooked up in a deal worth $760 million to create a new US-based firm focused on developing novel immune tolerance therapeutics.
 
Kanyos Bio, which is headquartered in Cambridge, Massachusetts, will initially work on clinical candidates for type I  diabetes and coeliac disease, although Astellas has the option to add a third autoimmune indication.
 
The firm will utilise Anokion’s tolerance-inducing technology shown to induce immune tolerance to protein drugs and autoimmune antigens in animal models, in an approach that the firm says “can be translated to virtually any protein in a myriad of clinical indications”. 
 
Astellas will provide non-dilutive research funding to Kanyos and holds an option to snap up the firm after reaching certain milestones, and will also take part in a $16 Million equity financing for new group alongside existing Anokion investors to secure some early cash.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach